GHRH Receptor Blockade Shows Promise for Heart Failure After Heart Attack
Background
Heart failure following a myocardial infarction (MI), commonly known as a heart attack, remains a significant cause of morbidity and mortality worldwide, often leading to progressive cardiac dysfunction. Current therapeutic strategies are limited in fully restoring cardiac function and preventing adverse remodeling, often leading to progressive ventricular dysfunction. This study investigates targeting the growth hormone-releasing hormone (GHRH) receptor as a novel approach to mitigate post-MI heart failure.
Results
Treatment with MIA-602 significantly improved cardiac function compared to controls. Ejection fraction (EF), a key measure of the heart's pumping ability, was increased by 43% (p<0.01) in the treated group, and fractional shortening (FS) was improved by 38% (p<0.01). MIA-602 treatment led to a significant reduction in myocardial fibrosis by 35% (p<0.05) and a decrease in cardiomyocyte apoptosis by 50% (p<0.01). Furthermore, the antagonist promoted angiogenesis (new blood vessel formation), evidenced by a 2.5-fold increase in capillary density (p<0.05), and modulated key signaling pathways involved in cardiac remodeling. These beneficial effects were linked to the downregulation of the GHRH receptor and its downstream targets.
Why It Matters
This research highlights a novel therapeutic strategy for heart failure post-MI by targeting the GHRH receptor, which is often overexpressed in damaged hearts and contributes to pathological remodeling. The significant improvements in cardiac function, reduced fibrosis, and enhanced angiogenesis suggest a powerful multi-modal benefit for cardiac repair. This approach could potentially lead to new clinical treatments for patients suffering from post-MI heart failure, offering a much-needed alternative to current therapies. Further preclinical validation in larger animal models and eventual Phase I/II human trials would be the logical next steps.